Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: investor (10)

ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou Basenese
investorvideoARCHIVE
ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou BaseneseJuly 30, 2024
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou Basenese
investorvideoARCHIVE
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou BaseneseJuly 17, 2024
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
press releaseinvestorARCHIVE
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne TechnologiesJuly 11, 2024
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors
investorvideoARCHIVE
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investorsJune 18, 2024
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024
investorvideoARCHIVE
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024June 11, 2024
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on NasdaqFebruary 12, 2024
Previous page
Page 10 of 10
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark